At present, only 2 GLP-1 RAs have been approved by the FDA for managing obesity: liraglutide, approved in 2014, and semaglutide, approved in 2020 [9]. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.